Videos

A fast-tracked once-daily pill aims to ease cannabis withdrawal by restoring CB1 signaling and reward-pathway balance as phase 3 enrollment surges.

APSARD nears publishing adult ADHD guidelines. Here's what resources you can expect to see upon their publication.

APSARD's US Adult ADHD Guidelines have advanced to Stage 3, the last review phase before a targeted fall 2026 publication.

A detailed case study reveals how positive, negative, and cognitive symptoms can persist for years even when a patient appears clinically stable, challenging the panel to define what genuine functional recovery should look like.

Despite effective treatments, most patients with schizophrenia go undertreated. The panel examines how stigma, fear, and outdated expectations for recovery continue to limit both patients and the clinicians who treat them.

Explore how hormones, labs, and medical conditions reshape psychiatric care—practical ordering tips and red flags from a new clinician-focused podcast.

Psychiatrist Craig Katz, MD, shows how resilience-based trauma care reduces stigma, avoids PTSD overdiagnosis, and guides patients.

New patients with cognitive complaints could need trauma screening; CBT shows promise after acute stress.

Before any prescription is written, non-pharmacologic strategies and a structured framework guide the panel's approach to agitation, alongside a biological explanation for why redirection so often fails.

Diagnosing adult ADHD demands more than a single office visit. The panel outlines the history-taking, collateral information, and follow-up structure needed to reach a confident, accurate diagnosis.

How disaster psychiatry shifts from forced debriefs to proactive outreach, from Ground Zero to COVID wards—building trauma-ready community care.

Adult ADHD is more common than clinicians assume, and its symptoms look different from the classic childhood presentation. The panel opens by reframing prevalence and heterogeneity as the foundation for accurate diagnosis.

Agitation does not stay contained to the patient. The panel examines the data linking agitation to caregiver burden, and the communication gaps that complicate coordinating care across specialties.

Learn insights from an early investigator of treatment-resistant depression and expert in the field.

Distinguishing agitation from depression, anxiety, and psychosis shapes everything that follows in treatment. The panel walks through the clinical differences and where formal screening scales genuinely fit into daily practice.

Agitation eventually affects nearly every patient with Alzheimer's disease, yet it rarely looks like simple aggression. The panel outlines how common it is, the many forms it takes, and why it so often goes unrecognized.

Clinicians learn how to assess and treat sexual dysfunction in depression, menopause, and psych meds—plus drug options that preserve desire and arousal.

How psilocybin, LSD, and mescaline hit 5‑HT2A—and why downstream signaling, not binding alone, may shape future psychedelic care.

Learn how gene variants shape CYP450 metabolism, receptors, and transporters—explaining intermediate phenotypes that influence psychiatric medication response.

HLP003 shows rapid, durable MADRS improvement in adjunctive MDD phase 2; phase 3 tests intermittent dosing to cut daily pill burden.

Amae Health links wearables, AI, and biomarkers to cut rehospitalizations—now racing to prove relapse prevention gains and unlock reimbursement.

Nardin Valentin, DO, debunks common hormone therapy myths and makes the case for HRT as standard in perimenopausal and menopausal psychiatric care.

Amae Health's chief medical officer argues mental health lacks the outcome measures primary care already uses, and that wearable biomarkers could fill that gap.

Why benzodiazepines still anchor acute anxiety care: when short-term use fits, how to spot red flags, and taper safely.

Miller urges psychiatry to look beyond DSM labels, weighing biological, psychological, social, cultural and spiritual factors to personalize care.

Amae Health's chief medical officer discusses why Fitbit, Oura, and Apple Watch data diverge, and how AI foundation models could soon make any wearable clinically useful.

Amae Health's chief medical officer says its treated patients see 30-day rehospitalization rates of 2% to 3%, vs 20% to 25% typically, though biomarkers' exact role remains unproven.

Nardin Valetin, DO, explains how to spot hormonally driven mood symptoms in perimenopause and when HRT can support psychiatric treatment.

GWAS supports psychiatry’s labels, but symptoms vary; speech biomarkers help pinpoint drivers and guide treatment across depression, OCD, schizophrenia.

Clinicians unpack integrated behavioral health: collaborative care, cross-training, and workforce gaps shaping better outcomes for severe mental illness.